83 related articles for article (PubMed ID: 20102207)
61. CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1.
Shen L; Chen YL; Huang CC; Shyu YC; Seftor REB; Seftor EA; Hendrix MJC; Chien DS; Chu YW
Pathol Oncol Res; 2023; 29():1611038. PubMed ID: 37351538
[TBL] [Abstract][Full Text] [Related]
62. Utilization of Water-Soluble Aminoethylamino-β-Cyclodextrin in the Pfitzinger Reaction-Catalyzed to the Synthesis of Diversely Functionalized Quinaldine.
Kim Y; Shinde VV; Jeong D; Jung S
Polymers (Basel); 2020 Feb; 12(2):. PubMed ID: 32050480
[TBL] [Abstract][Full Text] [Related]
63. Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.
Xiao Z; Morris-Natschke SL; Lee KH
Med Res Rev; 2016 Jan; 36(1):32-91. PubMed ID: 26359649
[TBL] [Abstract][Full Text] [Related]
64. Design and synthesis of new 2-arylnaphthyridin-4-ones as potent antitumor agents targeting tumorigenic cell lines.
Liu CY; Cheng YY; Chang LC; Huang LJ; Chou LC; Huang CH; Tsai MT; Liao CC; Hsu MH; Lin HY; Wu TS; Wen YF; Zhao Y; Kuo SC; Lee KH
Eur J Med Chem; 2015 Jan; 90():775-87. PubMed ID: 25528332
[TBL] [Abstract][Full Text] [Related]
65. Prodrugs of phosphonates and phosphates: crossing the membrane barrier.
Wiemer AJ; Wiemer DF
Top Curr Chem; 2015; 360():115-60. PubMed ID: 25391982
[TBL] [Abstract][Full Text] [Related]
66. Mechanistic studies on regioselective dephosphorylation of phosphate prodrugs during a facile synthesis of antitumor phosphorylated 2-phenyl-6,7-methylenedioxy-1H-quinolin-4-one.
Cheng YY; Liu CY; Huang LJ; Huang CH; Lee KH; Lin CT; Kuo SC
Molecules; 2013 Jul; 18(7):8028-45. PubMed ID: 23884134
[TBL] [Abstract][Full Text] [Related]
67. Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
Leung SC; Gibbons P; Amewu R; Nixon GL; Pidathala C; Hong WD; Pacorel B; Berry NG; Sharma R; Stocks PA; Srivastava A; Shone AE; Charoensutthivarakul S; Taylor L; Berger O; Mbekeani A; Hill A; Fisher NE; Warman AJ; Biagini GA; Ward SA; O'Neill PM
J Med Chem; 2012 Mar; 55(5):1844-57. PubMed ID: 22364417
[TBL] [Abstract][Full Text] [Related]
68. Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
Pidathala C; Amewu R; Pacorel B; Nixon GL; Gibbons P; Hong WD; Leung SC; Berry NG; Sharma R; Stocks PA; Srivastava A; Shone AE; Charoensutthivarakul S; Taylor L; Berger O; Mbekeani A; Hill A; Fisher NE; Warman AJ; Biagini GA; Ward SA; O'Neill PM
J Med Chem; 2012 Mar; 55(5):1831-43. PubMed ID: 22364416
[TBL] [Abstract][Full Text] [Related]
69. First synthesis of 2-(benzofuran-2-yl)-6,7-methylene dioxyquinoline-3-carboxylic acid derivatives.
Gao W; Liu J; Jiang Y; Li Y
Beilstein J Org Chem; 2011 Feb; 7():210-7. PubMed ID: 21445378
[TBL] [Abstract][Full Text] [Related]
70. Design and synthesis of 2-(3-benzo[b]thienyl)-6,7-methylenedioxyquinolin-4-one analogues as potent antitumor agents that inhibit tubulin assembly.
Chang YH; Hsu MH; Wang SH; Huang LJ; Qian K; Morris-Natschke SL; Hamel E; Kuo SC; Lee KH
J Med Chem; 2009 Aug; 52(15):4883-91. PubMed ID: 19719238
[TBL] [Abstract][Full Text] [Related]
71. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.
Jung FH; Pasquet G; Lambert-van der Brempt C; Lohmann JJ; Warin N; Renaud F; Germain H; De Savi C; Roberts N; Johnson T; Dousson C; Hill GB; Mortlock AA; Heron N; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Green S; Brown E; Thompson K; Brightwell S
J Med Chem; 2006 Feb; 49(3):955-70. PubMed ID: 16451062
[TBL] [Abstract][Full Text] [Related]
72. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
73. Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent.
Chou LC; Chen CT; Lee JC; Way TD; Huang CH; Huang SM; Teng CM; Yamori T; Wu TS; Sun CM; Chien DS; Qian K; Morris-Natschke SL; Lee KH; Huang LJ; Kuo SC
J Med Chem; 2010 Feb; 53(4):1616-26. PubMed ID: 20102207
[TBL] [Abstract][Full Text] [Related]
74. Design, synthesis, and preclinical evaluation of new 5,6- (or 6,7-) disubstituted-2-(fluorophenyl)quinolin-4-one derivatives as potent antitumor agents.
Chou LC; Tsai MT; Hsu MH; Wang SH; Way TD; Huang CH; Lin HY; Qian K; Dong Y; Lee KH; Huang LJ; Kuo SC
J Med Chem; 2010 Nov; 53(22):8047-58. PubMed ID: 20973552
[TBL] [Abstract][Full Text] [Related]
75. Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
Edsall AB; Agoston GE; Treston AM; Plum SM; McClanahan RH; Lu TS; Song W; Cushman M
J Med Chem; 2007 Dec; 50(26):6700-5. PubMed ID: 18052315
[TBL] [Abstract][Full Text] [Related]
76. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
